AKTS$14.598.41%-1.34
Aktis Oncology Inc (AKTS)
Date: 2026-11-02 16:00O: 16.01H: 16.01L: 13.96C: 14.59Vol: 898.2k
Aktis Oncology Inc stock is traded at $14.59, with a volume of 898,181. It is down -8.41% in the last 24 hours and down -21.22% over the past month. Aktis Oncology Inc is a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large patient populations, including those not addressed by existing platform technologies. The company specializes in developing targeted alpha radiopharmaceuticals for solid tumors such as breast, lung, colorectal, bladder, and liver cancers. Its pipeline products include AKY-1189 and AKY-2519, focusing on solid tumors. The company has one operating and reportable segment focused on the research and development of targeted radiopharmaceuticals to treat a broad range of solid tumor cancers. The company generates revenue from Collaboration agreement.
Previous Close:
$15.93
Open:
$16.01
24h Volume:
898,181
Relative Volume:
2.78
Market Cap:
$811.49M
Revenue:
$7.48M
Net Income/Loss:
-$60.50M
P/E Ratio:
-
EPS:
-$1.13
Net Cash Flow:
-$52.28M
1W Performance:
-11.31%
1M Performance:
-21.22%
6M Performance:
-24.87%
1Y Performance:
+39,120%
1-Day Range:
$0.00$0.00
1-Week Range:
$13.96$17.33
52-Week Range:
$0.033$34.19
Aktis Oncology Inc Stock (AKTS) Company Profile
Name
Aktis Oncology IncSector
HealthcareIndustry
BiotechnologyPhone
978-237-4380Address
17 DRYDOCK AVENUE, BOSTON, NC, USAMarket Cap
Revenue
Net Income
Cash Flow
EPS
Aktis Oncology Inc Stock (AKTS) Upgrades & Downgrades
Aktis Oncology Inc Stock (AKTS) Financials Data
Aktis Oncology Inc Stock (AKTS) Insider Trading
- Czibere AkosSep 23 '26Chief Medical Officer
- Transaction
- Option Exercise
- Cost
- $4.95
- #Shares
- 12,500
- Value ($)
- 61,875
- #Shares Total
- 12,500
- Czibere AkosSep 23 '26Chief Medical Officer
- Transaction
- Sale
- Cost
- $20.69
- #Shares
- 12,500
- Value ($)
- 258,621
- #Shares Total
- 0
- Akos CzibereSep 23 '26Officer
- Transaction
- Proposed Sale
- Cost
- $22.11
- #Shares
- 25,000
- Value ($)
- 552,750
- #Shares Total
- 0
- Herrmann KenJul 20 '26Director
- Transaction
- Sale
- Cost
- $24.56
- #Shares
- 4,856
- Value ($)
- 119,274
- #Shares Total
- 0
- KEN HERRMANNJul 20 '26Director
- Transaction
- Proposed Sale
- Cost
- $24.56
- #Shares
- 4,856
- Value ($)
- 119,275
- #Shares Total
- 0
- Herrmann KenJul 20 '26Director
- Transaction
- Option Exercise
- Cost
- $0.59
- #Shares
- 4,856
- Value ($)
- 2,859
- #Shares Total
- 4,856
- KEN HERRMANNJul 17 '26Director
- Transaction
- Proposed Sale
- Cost
- $25.21
- #Shares
- 3,065
- Value ($)
- 77,259
- #Shares Total
- 0
- Herrmann KenJul 17 '26Director
- Transaction
- Sale
- Cost
- $25.21
- #Shares
- 3,065
- Value ($)
- 77,259
- #Shares Total
- 0
- Herrmann KenJul 17 '26Director
- Transaction
- Option Exercise
- Cost
- $0.08
- #Shares
- 3,065
- Value ($)
- 245
- #Shares Total
- 3,065
- Ron-Bigger ShulamitJul 08 '26Chief Operating Officer
- Transaction
- Sale
- Cost
- $27.75
- #Shares
- 50,000
- Value ($)
- 1,387,558
- #Shares Total
- 0
